

#### MATERIAL SAFETY DATA SHEET

**Product Name: Epinephrine Injection, USP** 

# 1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name Hospira, Inc.

And Address 275 North Field Drive

Lake Forest, Illinois 60045

USA

Note: Hospira, formerly the Hospital Products Division of Abbott Laboratories, was

created as an independent company in May 2004.

**Emergency Telephone** 

CHEMTREC: 800 424-9300 224 212-2055

Hospira, Inc.

**Product Name** Epinephrine Injection, USP

Synonyms None

# 2. COMPOSITION/INFORMATION ON INGREDIENTS

 $\begin{array}{lll} \textbf{Ingredient Name} & Epinephrine \\ \textbf{Chemical Formula} & C_9H_{13}NO_3 \end{array}$ 

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Epinephrine	0.01	51-43-3	DO2625000
Water	99	7732-18-5	ZC0110000

## 3. HAZARD INFORMATION

**Emergency Overview** In clinical use, this material stimulates the sympathetic nervous system and the

heart. Target organs include the nervous system, eyes, cardiovascular system

and respiratory system.

**Occupational Exposure** 

Potential

Information on the absorption of this compound via ingestion,

inhalation or skin contact is not available. Avoid liquid aerosol generation and

skin contact with solution.

Signs and Symptoms No signs or symptoms from occupational exposure are known. Clinical data

suggests the following: nervousness, sweating, fearfulness, anxiety, palpitations, tenseness, restlessness, headache, tremor, dizziness, lightheadness, tachycardia, nausea, vomiting, respiratory difficulty, fever, chills, dilated pupils, blurred vision, cyanosis, electrocardiogram change, disturbed cardiac rhythm,

hypertension, metabolic acidosis, and cardiac injury.

**Medical Conditions Aggravated by Exposure**  Hypersensitivity to the material and/or similar materials. Pre-existing central nervous system, cardiovascular system, respiratory system ailments.

Product Name: Epinephrine Injection, USP

4. FIRST AID MEASURES

**Eye Contact:** Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

**Skin Contact:** Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

**Inhalation:** Remove from source of exposure. If signs of toxicity occur, seek medical

attention. Provide symptomatic / supportive care as necessary.

**Ingestion:** Remove from source of exposure. If signs of toxicity occur, seek medical

attention. Provide symptomatic / supportive care as necessary.

### 5. FIRE FIGHTING MEASURES

Flammability: Non-flammable.

Fire & Explosion

None

Hazard:

**Extinguishing Media:** Use extinguishing media appropriate for primary cause of fire.

**Special Fire Fighting** 

Procedures

No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal Absorb liquid with suitable material and clean affected area with soap and

water. Dispose of materials according to the applicable federal, state, or local

regulations.

#### 7. HANDLING AND STORAGE

**Handling** Protect from light by retaining in carton until contents have been used.

**Storage** No special storage required for hazard control. For product protection store at

controlled room temperature of 15-30°C (59-86°F).

**Special Precautions** Protect from freezing, light and extreme heat.

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

**Exposure Guidelines** 

La josufe Guidelines					
		Exposure limits			
Component	OSHA-PEL	ACGIH-TLV	Hospira EEL		
Epinephrine	8 hr TWA: Not	8 hr TWA: : Not	8 hr TWA: 1 mcg/m3		
	Established	Established	STEL: 20 mcg/m3		

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit

ACGIH TLV: American Conference of Governmental Industrial Hygienists - Threshold Limit Value.

EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.

**Product Name: Epinephrine Injection, USP** 

**Respiratory Protection** Respiratory protection is not needed during normal product use.

**Skin Protection** If solution contact with unprotected skin is likely, use of impervious gloves is a

prudent practice.

**Eye Protection** Eye protection is not required during expected product use conditions but may

be warranted should a splash potential exist.

**Engineering Controls** Engineering controls are not needed during normal product use conditions.

# 9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical

Clear liquid

State

Odor Not Determined

**Boiling Point** Approximately that of water (100 °C, 212 °F). **Freezing Point** Approximately that of water (0 °C, 32 °F).

**Vapor Pressure** Approximately that of water (17.5 mm Hg at 20 °C).

Vapor Density (Air=1) Not Applicable
Evaporation Rate Not Applicable
Bulk Density Not Determined

**Specific Gravity** Approximately that of water (1.0)

**Solubility** Aqueous solution

**pH** 2.5 - 5.0

# 10. STABILITY AND REACTIVITY

**Chemical Stability** Stable under standard use and storage conditions.

**Incompatibilities** None

**Hazardous** Toxic fumes of nitrogen oxides

Decomposition Products

Toxic funics of introgen oxides

**Hazardous** None

**Polymerization** 

## 11. TOXICOLOGICAL INFORMATION:

#### **Acute Toxicity - Oral:**

Ingredient(s)	Percent	Test Type	Value	Units	Species
Epinephrine	100	LD50	24-50	mg/kg	Rats, Mice

LD50 is the dosage producing 50% mortality. Product contains approximately 0.01% Epinephrine.

#### **Acute Toxicity - Dermal:**

Ingredient(s)	Percent	Test Type	Value	Units	Species
Epinephrine	100	LD50(sc)	62	mg/kg	Rats

LD50 (sc) is the value for skin contact.

**Mutagenicity** Epinephrine has produced mutagenic effects in some bioassays.

**Target Organ Effects** In clinical use target organ effects include the nervous system, eyes,

cardiovascular system and respiratory system.

**Product Name: Epinephrine Injection, USP** 

## 12. ECOLOGICAL INFORMATION:

Aquatic Toxicity Not Determined.

### 13. DISPOSAL CONSIDERATIONS:

Waste Disposal Disposal should be performed in accordance with the federal, state or local

regulatory requirements.

**Container Handling** Dispose of container and unused contents in accordance with federal, state,

and Disposal and local regulations.

### 14. TRANSPORTATION INFORMATION

**DOT** Not Regulated

Notes: DOT - US Department of Transportation Regulations

#### 15. REGULATORY INFORMATION

TSCA Status Not Regulated CERCLA Status Not Regulated SARA Status Not Regulated

RCRA Status Epinephrine is listed in 40CFR Part 261.33(e), Waste Code P042.

PROP 65 (Calif.) Not Regulated

Notes: TSCA Toxic Substance Control Act

CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act

SARA Superfund Amendments and Reauthorization Act RCRA US EPA, Resource Conservation and Recovery Act

Prop 65, California Proposition 65

# 16. OTHER INFORMATION:

MSDS Coordinator T. Straits MPH, CIH Date Prepared September 15, 2005

#### Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.